Base de dados : LILACS
Pesquisa : D08.811.150.240 [Categoria DeCS]
Referências encontradas : 2 [refinar]
Mostrando: 1 .. 2   no formato [Detalhado]

página 1 de 1

  1 / 2 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-625249
Autor: Cordeiro, Adriana Teixeira; Silva, Camila Morais Gonçalves da; Bartchewsky Júnior, Waldemar; Ribeiro, Marcelo Lima; Martinez, Carlos Augusto Real.
Título: Avaliação da expressão do gene MGMT nos tecidos normal e neoplásico de doentes com câncer colorretal / Evaluation of the expression of the MGMT gene in normal and neoplastic tissue of patients with colorectal cancer
Fonte: Rev. Col. Bras. Cir;39(1):48-53, 2012. ilus, tab.
Idioma: pt.
Resumo: OBJETIVO: Avaliar a expressão tecidual do gene de reparo MGMT comparando a mucosa cólica normal e neoplásica em doentes com câncer colorretal. MÉTODOS: Foram estudados 44 portadores de adenocarcinoma colorretal confirmado por estudo histopatológico. Foram excluídos doentes suspeitos de pertencerem a famílias com câncer colorretal hereditário (HNPCC e PAF) e os portadores de câncer do reto médio e inferior submetidos a tratamento quimioradioterápico neoadjuvante. A expressão do gene MGMT foi avaliada pela técnica da reação de polimerase em cadeia em tempo real (RT-PCR). A comparação dos resultados encontrados para expressão do gene MGMT entre tecidos normais e neoplásicos foi feita pelo teste t de Student pareado, adotando-se nível de significância de 5% (p <0,05). RESULTADOS: A expressão tecidual do gene MGMT em todos os doentes foi menor no tecido neoplásico quando comparada a do tecido normal (p=0,002). CONCLUSÃO: O gene de reparo MGMT encontra-se menos expresso no tecido neoplásico quando comparados aos tecidos normais em portadores de CCR esporádico.

OBJECTIVE: To evaluate the expression of tissue repair gene MGMT by comparing normal and neoplastic colonic mucosa in patients with colorectal cancer (CRC). METHODS: We studied 44 patients with colorectal cancer confirmed by histopathology. We excluded patients suspected of belonging to families with hereditary colorectal cancer (HNPCC and FAP) and patients with cancer of the lower or medium rectum treated with neoadjuvant chemoradiotherapy. The MGMT gene expression was assessed by the technique of polymerase chain reaction in real time (RT-PCR). The comparison of results for MGMT gene expression between normal and neoplastic tissues was made by paired Student's t test, adopting a significance level of 5% (p <0.05). RESULTS: Tissue expression of the MGMT gene in all patients was lower in tumor tissue when compared to normal tissue (p = 0.002). CONCLUSION: The repair gene MGMT is less expressed in tumor tissue compared to normal tissues in patients with sporadic CRC.
Descritores: Adenocarcinoma/genética
Neoplasias Colorretais/genética
Metilases de Modificação do DNA/genética
Enzimas Reparadoras do DNA/genética
Regulação Neoplásica da Expressão Gênica
Proteínas Supressoras de Tumor/genética
-Colo
Mucosa Intestinal
Limites: Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  2 / 2 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Rosemberg, Sérgio
Teixeira, Manoel Jacobsen
Marie, Suely Kazue Nagahashi
Texto completo
Id: lil-601909
Autor: Uno, Miyuki; Oba-Shinjo, Sueli Mieko; Camargo, Anamaria Aranha; Moura, Ricardo Pereira; Aguiar, Paulo Henrique de; Cabrera, Hector Navarro; Begnami, Marcos; Rosemberg, Sérgio; Teixeira, Manoel Jacobsen; Marie, Suely Kazue Nagahashi.
Título: Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
Fonte: Clinics;66(10):1747-1755, 2011. ilus, graf, tab.
Idioma: en.
Projeto: FAPESP; . CNPq.
Resumo: OBJECTIVES: 1) To correlate the methylation status of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter to its gene and protein expression levels in glioblastoma and 2) to determine the most reliable method for using MGMT to predict the response to adjuvant therapy in patients with glioblastoma. BACKGROUND: The MGMT gene is epigenetically silenced by promoter hypermethylation in gliomas, and this modification has emerged as a relevant predictor of therapeutic response. METHODS: Fifty-one cases of glioblastoma were analyzed for MGMT promoter methylation by methylation-specific PCR and pyrosequencing, gene expression by real time polymerase chain reaction, and protein expression by immunohistochemistry. RESULTS: MGMT promoter methylation was found in 43.1 percent of glioblastoma by methylation-specific PCR and 38.8 percent by pyrosequencing. A low level of MGMT gene expression was correlated with positive MGMT promoter methylation (p = 0.001). However, no correlation was found between promoter methylation and MGMT protein expression (p = 0.297). The mean survival time of glioblastoma patients submitted to adjuvant therapy was significantly higher among patients with MGMT promoter methylation (log rank = 0.025 by methylation-specific PCR and 0.004 by pyrosequencing), and methylation was an independent predictive factor that was associated with improved prognosis by multivariate analysis. DISCUSSION AND CONCLUSION: MGMT promoter methylation status was a more reliable predictor of susceptibility to adjuvant therapy and prognosis of glioblastoma than were MGMT protein or gene expression levels. Methylation-specific polymerase chain reaction and pyrosequencing methods were both sensitive methods for determining MGMT promoter methylation status using DNA extracted from frozen tissue.
Descritores: Neoplasias Encefálicas/genética
Metilases de Modificação do DNA/genética
Enzimas Reparadoras do DNA/genética
Glioblastoma/genética
Regiões Promotoras Genéticas/genética
Proteínas Supressoras de Tumor/genética
-Neoplasias Encefálicas/metabolismo
Metilação de DNA
Metilases de Modificação do DNA/metabolismo
Enzimas Reparadoras do DNA/metabolismo
Expressão Gênica
Glioblastoma/metabolismo
Imuno-Histoquímica
Estimativa de Kaplan-Meier
Reação em Cadeia da Polimerase
Valor Preditivo dos Testes
Prognóstico
Estatísticas não Paramétricas
Fatores de Tempo
Proteínas Supressoras de Tumor/metabolismo
Limites: Adolescente
Adulto
Idoso
Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde